Chronic Intestinal Pseudo-Obstruction Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled, Cross-Over, Multiple (n=1) Trial to Evaluate the Effects of R093877 in Patients With Chronic Intestinal Pseudo-Obstruction (CIP).
This study was designed to investigate the clinical safety, tolerability and efficacy of prucalopride in improving the symptoms associated with chronic intestinal pseudo-obstruction (CIP) in subjects with CIP. The study hypothesis was that prucalopride at doses up to 4 mg is safe, well tolerated, efficacious and improves the symptoms associated with CIP.
This phase II, double-blind, placebo-controlled, two-treatment four periods cross-over trial
investigated the clinical safety, tolerability and the efficacy of R093877 (prucalopride) in
improving the symptoms associated with chronic intestinal pseudo-obstruction (CIP) in
subjects with CIP.
Subjects were treated for 4 periods of 12 weeks each with either R093877 2 mg (2 periods) or
placebo (2 periods). In each of the first and second 6 month period, there was a placebo
(PLA) and an active drug (PRU) treatment period. There were no wash-out periods. In total,7
subjects were randomized; 2 were assigned to the PLA-PRU-PLA-PRU, 2 to the PRUPLA-PRU-PLA, 2
to the PLA-PRU-PRU-PLA, and 1 to the PRU-PLA-PLA-PRU sequence group. Subjects were allowed
to use up to 4 mg of prucalopride per day if the 2 mg dose seemed to be insufficient. Two
subjects used an average of 3 mg of prucalopride per day during the active drug periods.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04506593 -
Indiana University Gastrointestinal Motility Diagnosis Registry
|
||
Recruiting |
NCT04193735 -
Pseudo-obstruction Assessment With MRI
|
||
Active, not recruiting |
NCT04118699 -
Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial
|
Phase 2 | |
Active, not recruiting |
NCT05724069 -
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
|
Phase 2 |